Aspen manufacturing is expected to drive the group’s earnings growth in the 2027 financial year, as the company works to replace business lost when a major mRNA production contract ended. Aspen Pharmacare forecasts that manufacturing EBITDA will more than double this year, according to its 2026 integrated report. Sterile Operations Offset Contract Loss In the year to end-June, factory EBITDA…